Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 6 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

2Total
Not Applicable (2)

Trial Status

Recruiting3
Unknown1
Enrolling By Invitation1
Not Yet Recruiting1

Clinical Trials (6)

Showing 6 of 6 trials
NCT05021029Enrolling By Invitation

UC Davis Cohort of Pre-Malignant and Malignant Gastro-Intestinal DisEases Study

NCT06272500Not ApplicableRecruitingPrimary

Safety and Efficacy Study of Betaine Hydrochloride in Treating Hypergastrinemia in Patients With Autoimmune Gastritis

NCT06946706RecruitingPrimary

Assessing the Prevalence and Epidemiological Characteristics of Small Intestinal Bacterial Overgrowth (SIBO) in Patients With Autoimmune Gastritis(AIG) Through Hydrogen and Methane Breath Testing(HMBT).

NCT06881511Not ApplicableRecruitingPrimary

Exploratory Study on the Efficacy of Betaine Hydrochloride in Treating Autoimmune Gastritis

NCT06557252Not Yet RecruitingPrimary

The Application of the PDCA Management Model in Improving the Diagnostic Accuracy of AIG

NCT05820607UnknownPrimary

Clinical Characteristics, Lifestyle and Multi-omics Analysis in Autoimmune Gastritis

Showing all 6 trials

Research Network

Activity Timeline